benserazide has been researched along with Myoclonic Jerk in 4 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A myoclonic syndrome consisting of tremor, myoclonus, and seizures was produced following the systemic administration of 5-hydroxytryptophan to adult rats previously given intracisternal injections of 5,7-dihydroxytryptamine and systemic desmethylimipramine, but not in their controls." | 3.65 | Myoclonus after 5-hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system. ( Baldessarini, RJ; Cancian, D; Growdon, JH; Stewart, RM, 1976) |
| "Postanoxic myoclonus was first accepted as being related to a dysfunction of the ventrolateral thalamic nucleus." | 1.26 | Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor. ( Beretta, E; de Crousaz, G; Regli, F; Steck, AJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sturchio, A | 1 |
| Gastaldi, M | 1 |
| Cariddi, LP | 1 |
| Biacchi, D | 1 |
| Espay, AJ | 1 |
| Franciotta, D | 1 |
| Versino, M | 1 |
| Mauri, M | 1 |
| Beretta, E | 1 |
| Regli, F | 1 |
| de Crousaz, G | 1 |
| Steck, AJ | 1 |
| Stewart, RM | 1 |
| Growdon, JH | 1 |
| Cancian, D | 1 |
| Baldessarini, RJ | 1 |
| Lauerma, H | 1 |
4 other studies available for benserazide and Myoclonic Jerk
| Article | Year |
|---|---|
Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Benserazide; Dopamine Agents; Drug | 2021 |
Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
Topics: 5-Hydroxytryptophan; Benserazide; Humans; Hydrazines; Hydroxyindoleacetic Acid; Hypoxia; Male; Middl | 1981 |
Myoclonus after 5-hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Dose-Response Relationship, Drug; Drug Interaction | 1976 |
Nocturnal wandering caused by restless legs and short-acting benzodiazepines.
Topics: Anti-Anxiety Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; My | 1991 |